Morgan Stanley Maintains Underweight on Integra Lifesciences, Lowers Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Drew Ranieri maintains an Underweight rating on Integra Lifesciences (IART) and lowers the price target from $37 to $24.

May 07, 2024 | 4:39 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley analyst Drew Ranieri maintains an Underweight rating on Integra Lifesciences and lowers the price target from $37 to $24.
The reduction in price target by a significant margin from $37 to $24 by a major financial institution like Morgan Stanley, coupled with the maintenance of an Underweight rating, suggests a bearish outlook on the stock. This could lead to negative investor sentiment and potentially a decrease in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100